Amalgamated Bank increased its position in shares of Juno Therapeutics Inc (NASDAQ:JUNO) by 14.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,131 shares of the biopharmaceutical company’s stock after purchasing an additional 1,642 shares during the quarter. Amalgamated Bank’s holdings in Juno Therapeutics were worth $600,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently made changes to their positions in JUNO. Capital International Investors bought a new position in Juno Therapeutics during the third quarter worth $256,339,000. Orbimed Advisors LLC lifted its stake in Juno Therapeutics by 123.1% during the third quarter. Orbimed Advisors LLC now owns 2,041,608 shares of the biopharmaceutical company’s stock worth $91,587,000 after purchasing an additional 1,126,400 shares during the last quarter. Capital Guardian Trust Co. bought a new stake in Juno Therapeutics in the third quarter valued at $37,400,000. Janus Henderson Group PLC bought a new stake in Juno Therapeutics in the third quarter valued at $37,351,000. Finally, Capital International Ltd. CA bought a new stake in Juno Therapeutics in the third quarter valued at $14,777,000. Hedge funds and other institutional investors own 70.19% of the company’s stock.
A number of research firms have issued reports on JUNO. JPMorgan Chase reiterated a “hold” rating on shares of Juno Therapeutics in a research note on Thursday, January 11th. Raymond James Financial reiterated a “buy” rating on shares of Juno Therapeutics in a research note on Thursday, January 11th. Barclays cut Juno Therapeutics from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $55.00 to $87.00 in a research note on Wednesday, January 24th. Wells Fargo cut Juno Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, December 12th. Finally, Standpoint Research reiterated a “hold” rating on shares of Juno Therapeutics in a research note on Wednesday, January 24th. One research analyst has rated the stock with a sell rating, eighteen have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $52.55.
In related news, EVP Robert Azelby sold 4,157 shares of Juno Therapeutics stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $85.55, for a total transaction of $355,631.35. Following the transaction, the executive vice president now directly owns 89,614 shares of the company’s stock, valued at $7,666,477.70. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Richard Klausner sold 12,724 shares of Juno Therapeutics stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $48.21, for a total value of $613,424.04. Following the transaction, the director now directly owns 741,499 shares in the company, valued at $35,747,666.79. The disclosure for this sale can be found here. Insiders have sold 426,465 shares of company stock worth $24,946,548 over the last three months. Corporate insiders own 15.08% of the company’s stock.
Shares of JUNO remained flat at $$86.96 during trading hours on Friday. The stock had a trading volume of 2 shares, compared to its average volume of 5,484,542. The company has a current ratio of 3.61, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01. Juno Therapeutics Inc has a 52 week low of $19.62 and a 52 week high of $87.01.
ILLEGAL ACTIVITY WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/08/amalgamated-bank-acquires-1642-shares-of-juno-therapeutics-inc-juno.html.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.